Literature DB >> 22421298

Functional measurement of coronary stenosis.

Nico H J Pijls1, Jan-Willem E M Sels.   

Abstract

Fractional flow reserve (FFR) is considered nowadays as the gold standard for invasive assessment of physiologic stenosis significance and an indispensable tool for decision making in coronary revascularization. Use of FFR in the catheterization laboratory accurately identifies which lesions should be stented and improves the outcome in most elective clinical and angiographic conditions. Recently, FFR has been upgraded to a class IA classification in multivessel percutaneous coronary intervention in the guidelines on coronary revascularization of the European Society of Cardiology. In this state-of-the-art paper, the basic concept of FFR and its application, characteristics, and use in several subsets of patients are discussed from a practical point of view. Copyright Â
© 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22421298     DOI: 10.1016/j.jacc.2011.09.077

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  73 in total

Review 1.  Coronary physiology assessment in the catheterization laboratory.

Authors:  Felipe Díez-Delhoyo; Enrique Gutiérrez-Ibañes; Gerard Loughlin; Ricardo Sanz-Ruiz; María Eugenia Vázquez-Álvarez; Fernando Sarnago-Cebada; Rocío Angulo-Llanos; Ana Casado-Plasencia; Jaime Elízaga; Francisco Fernández Avilés Diáz
Journal:  World J Cardiol       Date:  2015-09-26

2.  How to differentiate the etiology of LV dysfunction as to whether it is "ischemic cardiomyopathy" or "dilated non-ischemic cardiomyopathy"? Invasive coronary and myocardial assessment is the approach of first choice.

Authors:  Sung Gyun Ahn; Habib Samady
Journal:  J Nucl Cardiol       Date:  2015-07-08       Impact factor: 5.952

Review 3.  The Role of Fractional Flow Reserve and Instantaneous Wave-Free Ratio Measurements in Patients with Acute Coronary Syndrome.

Authors:  Abdul Rahman Ihdayhid; Jin-Sin Koh; John Ramzy; Arnav Kumar; Michael Michail; Adam Brown; Habib Samady
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

4.  Left ventricular end-diastolic pressure affects measurement of fractional flow reserve.

Authors:  Robert A Leonardi; Jacob C Townsend; Chetan A Patel; Bethany J Wolf; Thomas M Todoran; Valerian L Fernandes; Christopher D Nielsen; Daniel H Steinberg; Eric R Powers
Journal:  Cardiovasc Revasc Med       Date:  2013-07-23

5.  Does rich coronary collateral circulation distal to chronically occluded left anterior descending artery compete with graft flow?

Authors:  Daisuke Kaku; Atsushi Nakahira; Hidekazu Hirai; Yasuyuki Sasaki; Mitsuharu Hosono; Yasuyuki Bito; Yasuo Suehiro; Shigefumi Suehiro
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-08-19

6.  Fractional flow reserve guided revascularization in daily practice: clinical judgment does not always meet science.

Authors:  Ronen Rubinshtein; Ronen Jaffe
Journal:  Cardiovasc Diagn Ther       Date:  2013-09

7.  Fractional flow reserve application in everyday practice: adherence to clinical recommendations.

Authors:  Katia Orvin; Tamir Bental; Alon Eisen; Hana Vaknin-Assa; Abid Assali; Eli I Lev; David Brosh; Ran Kornowski
Journal:  Cardiovasc Diagn Ther       Date:  2013-09

Review 8.  Myocardial ischemia is a key factor in the management of stable coronary artery disease.

Authors:  Kohichiro Iwasaki
Journal:  World J Cardiol       Date:  2014-04-26

9.  Simultaneous evaluation of plaque stability and ischemic potential of coronary lesions in a fluid-structure interaction analysis.

Authors:  Xinlei Wu; Clemens von Birgelen; Su Zhang; Daixin Ding; Jiayue Huang; Shengxian Tu
Journal:  Int J Cardiovasc Imaging       Date:  2019-05-03       Impact factor: 2.357

Review 10.  Recent insights into the treatment of stable CAD : FFR-guided PCI vs. medical therapy.

Authors:  L X van Nunen; P A L Tonino
Journal:  Herz       Date:  2013-06       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.